Thrivent Financial for Lutherans Sells 150,280 Shares of CorVel Corp. $CRVL

Posted by Francis Steltz on May 18th, 2026

Thrivent Financial for Lutherans reduced its stake in shares of CorVel Corp. (NASDAQ:CRVL – Free Report) by 32.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 308,046 shares of the business services provider’s stock after selling 150,280 shares during the quarter. Thrivent Financial for Lutherans owned about 0.60% of CorVel worth $20,845,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in CRVL. Royal Bank of Canada increased its stake in shares of CorVel by 12.5% in the 1st quarter. Royal Bank of Canada now owns 51,261 shares of the business services provider’s stock valued at $5,739,000 after buying an additional 5,703 shares during the period. AQR Capital Management LLC raised its holdings in CorVel by 4.0% during the 1st quarter. AQR Capital Management LLC now owns 26,468 shares of the business services provider’s stock worth $2,964,000 after purchasing an additional 1,013 shares during the last quarter. Integrated Wealth Concepts LLC raised its holdings in CorVel by 11.4% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,800 shares of the business services provider’s stock worth $425,000 after purchasing an additional 389 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in CorVel by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,846 shares of the business services provider’s stock worth $1,774,000 after purchasing an additional 702 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in CorVel by 127.4% during the 1st quarter. Millennium Management LLC now owns 48,182 shares of the business services provider’s stock worth $5,395,000 after purchasing an additional 26,990 shares during the last quarter. 51.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at CorVel

In other news, insider Maxim Shishin sold 2,400 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $54.00, for a total value of $129,600.00. Following the completion of the transaction, the insider owned 7,050 shares in the company, valued at $380,700. This represents a 25.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 44.56% of the stock is owned by company insiders.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

View Our Latest Analysis on CorVel

CorVel Stock Performance

Shares of NASDAQ:CRVL opened at $57.11 on Monday. CorVel Corp. has a 52 week low of $44.83 and a 52 week high of $117.22. The company has a market capitalization of $2.92 billion, a PE ratio of 28.00 and a beta of 0.98. The company has a 50 day moving average price of $55.13 and a two-hundred day moving average price of $62.10.

CorVel Profile

(Free Report)

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).